分子亚型和2023年FIGO在子宫内膜癌中的分期:重新定义辅助疗法
Hao Lin1, Yu-Che Ou2, Hung-Chun Fu2
1Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan; School of Medicine, National Sun-Yat Sen University, Kaohsiung, Taiwan.
Taiwanese journal of obstetrics & gynecology
|July 2, 2025
概括
2023年FIGO对子宫内膜癌的分期更新整合了针对量身定制的辅助治疗的分子概况. 像POLE突变和dMMR这样的分子亚型显著影响治疗决策和患者的结果.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子病理学分子病理学
- 临床瘤学临床瘤学
背景情况:
- 2023年FIGO对子宫内膜癌的分期系统结合了分子亚型来改进治疗策略.
- 分子分类 (POLE突变,dMMR,p53异常) 对于个性化辅助治疗至关重要.
- 传统的分期仅仅是不足以指导子宫内膜癌的治疗.
研究的目的:
- 评估更新的FIGO分期系统对子宫内膜癌治疗的影响,包括分子亚型.
- 根据分子形状和疾病阶段分析不同辅助疗法的疗效.
- 突出分子分类在个性化子宫内膜癌管理中的不断变化的作用.
主要方法:
- 基于2023年FIGO分期和分子分类 (POLE,dMMR,p53,激素受体) 的临床数据和治疗结果的分析.
- 对免疫疗法和激素疗法疗效的现实数据和临床试验结果 (例如,RUBY,NRG-GY018) 的审查.
- 评估正在进行的试验 (例如,RAINBO p53abn-RED),评估高风险群体的新型辅助治疗.
主要成果:
- FIGO I/II期POLE突变和非TP53突变瘤通常具有良好的结果,通常不需要辅助治疗.
- 治疗IIA/IIC阶段非POLE突变子宫内膜癌仍然存在争议,辅助化疗/放射治疗的益处有限.
- 第三阶段的POLE突变瘤显示出良好的预后;免疫疗法对III/IV阶段的dMMR患者有效.
- 激素受体状态是非特异性分子亚型的关键预后标志物,表明激素治疗的潜力.
- 突变TP53的瘤表明预后不佳,目前正在进行试验,探索像olaparib.com这样的向疗法.
结论:
- 将分子亚型与2023年FIGO分期系统相结合,在子宫内膜癌中彻底改变了辅助治疗决策.
- 基于分子形状的个性化治疗策略显著改善了患者的治疗结果.
- 需要进一步的研究,以优化特定分子子组和高风险患者的辅助疗法.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...